echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Good news - FACI magnesium stearate is activated!

    Good news - FACI magnesium stearate is activated!

    • Last Update: 2022-04-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    FACI Magnesium Stearate

    F20180001533


    A



    about 

    FACI

    Faci Asia Pacific Pte Ltd was established in 1999 and is located in Jurong Island, Singapore and is wholly owned by Faci SpA


    The pharmaceutical excipients produced by the Singapore factory mainly include magnesium stearate, calcium stearate, sodium stearate, and zinc stearate



    Product Regulatory Advantages

    01100% plant origin

    02Pharmaceuticalgrade, in line with national pharmacopoeia

    Compliant with USP, EP, BP, JP, ChP

    US FDA DMF No.


    China CDE registration number F20180001533

    03Completecertification

    ISO, HACCP, Kosher, HALAL, RSPO


    Production Process

    It is produced by the international mainstream one-step reaction method.



    Factors Affecting Formulations

    01Relative content of stearic acid and palmitic acid

    Pharmacopoeia: C18 > 40%, C16 + C18 >90%

    High content of C18 - good lubrication effect - good flow of powder and good compressibility of tablet

    The composition of stearic acid affects the crystal form of magnesium stearate


    02Free fatty acid content 

    Pharmacopoeia: <0.


    Adverse reactions with tablet formulation ingredients

    Limits depend on process and formulation stability studies


    03Unreacted MgO

    The reaction process of magnesium salts may reduce the lubricating effect;

    Hydrophobic, potentially affecting mobility


    04 Bulk density 

    Differences in particle size and structure , as well as particle-particle interactions , determine differences in bulk density

    Differences in bulk and compacted densities predict powder flowability

    Affect tableting pressure


    05Residual through 200 mesh sieve

    Large particles reduce coating effectiveness

    Large particles cause aggregation


    06Appropriate particle size distribution range

    Smaller particle size—larger specific surface area

    But smaller particles require more coating, extending drug release time

    Higher magnesium stearate content resulted in higher tablet friability


    Narrower particle size distribution for smoother coating

    Based on the characteristics of each component of the tablet, select the appropriate particle size distribution range


    07Suitable specific surface area

    Large specific surface area, more uniform coating and better fluidity

    However, the larger the specific surface area, the lower the tablet hardness



    Scan the code to get samples

    Agency brand

    JRS|EVONIK|MERCK

    ACG|INGREDION

    FACI|OMYA

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.